Estrella Immunopharma- Warrants (29/09/2028) Operating Income

As of the most recent data (June 2026), ESLAW shows a operating income of $-9.7M. That compares with $-12M in the prior-year period — up 19.8% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ESLAW's operating income is now $-9.7M (was $-12M) — a 19.8% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Estrella Immunopharma- Warrants (29/09/2028) is outperforming or lagging.

Tracking ESLAW's operating income over time shows whether Estrella Immunopharma- Warrants (29/09/2028) is scaling, shrinking, or reshaping that part of the business. The current reading is $-9.7M That compares with $-12M in the prior-year period — up 19.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this operating income page, Stockcircle has Estrella Immunopharma- Warrants (29/09/2028)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect operating income (currently $-9.7M) with ownership activity and broader fundamentals.